Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides Trial in Progress poster on IPH4502, Innate’s differentiated ADC in development in advanced solid tumors...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in...

€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET ® program in autoimmune indications First patient dosed in a Phase 1 study...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2024 Universal Registration Document (Document d’enregistrement universel) for...

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated superior preclinical anti-tumor activity...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET ® program in autoimmune indications, and more Innate Pharma SA...

Innate to regain its rights on CD123 targeting ANKET ® SAR443579 (SAR’579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through a capital...